Trial Profile
An observational study evaluating the real time clinical safety and effectiveness of Saroglitazar in patients with diabetic dyslipiemia
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Jul 2017
Price :
$35
*
At a glance
- Drugs Saroglitazar (Primary)
- Indications Dyslipidaemias
- Focus Adverse reactions; Therapeutic Use
- 19 Jul 2017 New trial record
- 13 Jun 2017 Results presented at the 77th Annual Scientific Sessions of the American Diabetes Association